Af­ter slic­ing and dic­ing TCRs for 8 years, Swedish biotech re­loads to an­gle for a spot in crowd­ed cell ther­a­py space

Södertäl­je, Swe­den, the his­toric home to the As­tra half of As­traZeneca, may seem an un­like­ly place for cut­ting-edge R&D on T cell re­cep­tors and cell ther­a­pies. And Rea­gan Jarvis — a trans­plant from New Zealand who had spent his aca­d­e­m­ic years study­ing in­nate im­mune sig­nal­ing — read­i­ly ad­mits he doesn’t fit your usu­al mold for a biotech founder.

But that’s where Jarvis found him­self eight years ago af­ter meet­ing Mikael Blomqvist, a Swedish en­tre­pre­neur who asked him to pitch some ideas for a new com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER